title: Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
abstract: Targeted therapies represent a major breakthrough in the treatment of adult acute lymphoblastic leukaemia (ALL). Because lymphoblastic leukaemia cells express a variety of specific antigens, those ones can serve as targets for monoclonal antibodies (MoAbs). Anti-CD20 (rituximab), anti-CD19 (blinatumomab, SAR3419), anti-CD22 (epratuzumab, inotuzumab ozogamicin) and anti-CD52 (alemtuzumab) have therefore been developed. Possible strategies even include recruitment of CD3 cytotoxic T cells (blinatumomab) or adoptive T-cell therapy by gene transfer of CD19-chimeric antigen receptors (CD19-CARs). Recent data show that antibody-based therapy is a highly promising treatment approach. However, optimal treatment approach still needs to be defined.
authors: Hematology Department, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre Bénite, France.
authors: Caroline
authors: C
authors: Le Jeune
authors: Xavier
authors: X
authors: Thomas
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000235:genetics / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy; D015870:Gene Expression; D015316:Genetic Therapy; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive; D058990:Molecular Targeted Therapy; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D000970:Antineoplastic Agents
keywords: acute lymphoblastic leukaemia; monoclonal antibodies; prognosis; therapy